Current - 4 hours ago

* Portfolio

* Team

* News

* Contact

* Investor Portal

Select Page

Portfolio

We don’t do incremental.

We like outliers.

The big ideas that shake things up.

Created with Snap

* All

* ACQUIRED: BEAM

* ACQUIRED: EXAS

* ACQUIRED: MSFT

* ACQUIRED: NEUMORA

* ACQUIRED:ILMN

* ACQUIRED:PACB

* Digital Health

* Gene Editing

* Medical Technology

* Proteomics

* PUBLIC

* PUBLIC | CMPX

* PUBLIC | NASDAQ:DNLI

* PUBLIC | NASDAQ:EDIT

* PUBLIC | NASDAQ:NMRA

* PUBLIC | NASDAQ:TWST

* PUBLIC | NASDAQ:VERV

ACQUIRED: NEUMORA, PUBLIC

ACQUIRED: NEUMORA, PUBLIC

ACQUIRED: MSFT, PUBLIC

PUBLIC, PUBLIC | CMPX

PUBLIC, PUBLIC | NASDAQ:DNLI

PUBLIC, PUBLIC | NASDAQ:EDIT

ACQUIRED:ILMN, PUBLIC

ACQUIRED: BEAM, PUBLIC

PUBLIC, PUBLIC | NASDAQ:NMRA

ACQUIRED:PACB, PUBLIC

ACQUIRED: EXAS, PUBLIC

PUBLIC, PUBLIC | NASDAQ:TWST

PUBLIC, PUBLIC | NASDAQ:VERV

Digital Health

Digital Health

Medical Technology

Gene Editing

Proteomics

Digital Health

CASE STUDY

EDITAS MEDICINE

From Early-Stage Science to IPO

Editas Medicine is harnessing CRISPR-Cas9 gene editing to create genomic medicines for devastating and hard-to-treat diseases, including Usher syndrome and Duschenne muscular dystrophy.

Biomatics Capital’s Dr. Boris Nikolic identified CRISPR as a very powerful game changing technology, after learning of the company through his academic and venture network.

In 2015, the partners of Biomatics played a key role in driving Editas to the next level of growth by leading a $120 million Series B round, marking the largest financial investment to a CRISPR startup. Nikolic joined the board and took an active role in guiding the company to a $94.4 million IPO, which was oversubscribed even in a difficult market.

B

Led $120 million Series B in August 2015

B

Negotiatied term sheet valuation

B

Joined board of directors

B

$94.4 million oversubscribed IPO in February 2016

© Copyright 2024 Biomatics Capital